These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 30253203

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib.
    Li W, Sparidans RW, Martins MLF, El-Lari M, Lebre MC, van Tellingen O, Beijnen JH, Schinkel AH.
    Mol Cancer Ther; 2021 Jun; 20(6):1173-1182. PubMed ID: 33785654
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2018 Oct 15; 143(8):2029-2038. PubMed ID: 29744867
    [Abstract] [Full Text] [Related]

  • 8. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH.
    Int J Pharm; 2019 Feb 10; 556():172-180. PubMed ID: 30553002
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
    van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.
    Mol Pharm; 2018 Nov 05; 15(11):5124-5134. PubMed ID: 30247919
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jul 05; 32(7):2205-16. PubMed ID: 25563977
    [Abstract] [Full Text] [Related]

  • 15. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
    Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, Schinkel AH.
    Clin Cancer Res; 2009 Apr 01; 15(7):2344-51. PubMed ID: 19276246
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2012 Jan 01; 130(1):223-33. PubMed ID: 21351087
    [Abstract] [Full Text] [Related]

  • 18. ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.
    Martínez-Chávez A, Loos NHC, Lebre MC, Tibben MM, Rosing H, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2022 Apr 01; 178():105954. PubMed ID: 34700018
    [Abstract] [Full Text] [Related]

  • 19. ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability.
    Li W, Lehutová D, Sparidans RW, Heydari P, Wang J, Lebre MC, Beijnen JH, Schinkel AH.
    Eur J Pharm Biopharm; 2022 Aug 01; 177():135-146. PubMed ID: 35772614
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.